foxo4-dri senolytic or senomorphic Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment Heterogeneity of Cellular Senescence, Senotyping,
Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases Targeting Cellular Senescence in Aging and Age Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway FOXO4 DRI UK Senolytic Peptide Research Peptides Lab UK The FOXO4 peptide in a DRI conformation (D amino acids in a retro reversed sequence), henceforth named FOXO4 DRI, competes with FOXO4 for p53 binding in a dose dependent manner and doing so with higher affinity. Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv
Pay in 4 interest-free payments of $6.67 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1



